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Abstract: As newer therapies for lung cancer are being explored it
becomes more important to understand the natural history of lung
cancer. A systematic review of the data shows that untreated lung
cancer is almost uniformly rapidly fatal, even if it is stage I. Analysis
of data regarding tumor volume doubling times shows that conven-
tionally detected lung cancers have short mean doubling times, and
only a small proportion with very long doubling times. Lung cancers
found during the course of a CT screening program have markedly
longer mean doubling times and a substantially greater proportion
with very long doubling times (400 days). Models of tumor
growth, however, are not understood well enough to use the ob-
served doubling time to predict length of survival without treatment.
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Many things are changing in the field of lung cancer,including newer treatments (sublobar resection, radio-
frequency ablation, cyberknife, and stereotactic radiosurgery)
and different methods of presentation (incidental detection on
computed tomography (CT) in an asymptomatic patient).1,2
Results for such interventions have been reported in many
nonrandomized studies. The implied argument is generally
that the results substantiate the value of the intervention
because the outcome is better than if nothing had been done.
This calls into question how well we actually know what
would have happened if nothing was done to treat a lung
cancer. This article seeks to carefully and systematically
review the available data regarding the natural history of lung
cancer. The primary focus is on early stage (I, II) non-small
cell lung cancer (NSCLC), as these patients are the primary
focus of most of the newer treatment methods.
Natural history is defined as patient survival in the
absence of any active treatment for the cancer. Supportive
care measures that palliate specific symptoms are allowed,
but not a treatment intended to affect the growth of cancer
cells. This may be somewhat ambiguous at times, for exam-
ple in the case of radiotherapy that is given to shrink a
particular focus of tumor blocking an airway or in the brain
(while such treatments are given primarily to relieve symp-
toms, they can significantly affect the length of survival).
However, there is general agreement that supportive care
measures are permissible when evaluating the natural history
of a tumor. Supportive care measures include pain medica-
tions, lower dose radiotherapy (50 Gy) intended to palliate
a particular symptom or a surgical procedure intended to
palliate a symptom or a local problem. Active treatment is not
allowed, such as surgical resection, chemotherapy, and radio-
therapy given at higher doses with curative intent.
There are two main ways to assess the natural history.
The most obvious is to follow the outcomes of patients who
were not treated with any therapeutic intervention (other than
basic supportive care). Direct measurement of the natural
history is simple but may be difficult to generalize. Those
patients who choose or are chosen not to receive any active
treatment may be quite different from those receiving treat-
ments, because of comorbidities, psychologic or social issues,
all of which have been shown to affect survival.3,4 The
differences in the characteristics of treated and untreated
patients are perhaps most marked in patients with early stage
lung cancer, in whom definition of the natural history is most
important.
Another way to estimate survival without treatment is
based on observation of the tumor over a period of time, after
which an intervention is (usually) undertaken. Estimation of
the natural history from a period of observation is probably
much more representative of the broad patient population
with lung cancer. A period of observation may be more likely
to have occurred in patients with slow growing tumors,
although it is likely that this selection bias is relatively low.
This suppositive is based on the high frequency of missed
lesions seen retrospectively on chest radiographs and the fre-
quency of an inherent period of observation of CT-detected
lesions (e.g., interval between screening CT and diagnostic CT).
However, there is uncertainty about how well the behavior
during the period of observation can be extrapolated throughout
the life of the tumor.5
METHODS
This review was prepared by following, as closely as
possible, published criteria for a systematic review, even
though no widely endorsed standard exists.6,7 The purpose of
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the project was to define the natural history of untreated lung
cancer, and to define growth rates on lung cancer during a
period of observation. Specific questions were whether the
natural history or growth rates were related to the years
included, the histologic cancer type, gender, radiographic
appearance, geographic location, the type of study (registry,
institutional series etc.) or the method of detection.
The search was designed to find all articles providing
data on the natural history and growth rates of NSCLC. We
searched three electronic databases (MEDLINE, EMBASE,
and the Cochrane Library) for original studies published
between 1960 and 2007 that provided data on either the
natural history of lung cancer or on the growth rate of
untreated NSCLC. We also manually searched the reference
sections of all studies identified electronically. The search
strategies are available on request from the author. The search
was limited to articles published in English. No source of
funding was available for this study.
We included articles reporting data on the natural
history of untreated patients with NSCLC or on tumor growth
rates in the absence of treatment. Both prospective and
retrospective study designs were included. Studies providing
data on fewer than 20 patients were excluded, as were studies
that reported primarily on cases of small-cell lung cancer. No
unpublished data were considered. We considered all dupli-
cate publications, but did not list data pertaining to the same
cohort of patients twice in the tables (we included cohorts
involving some overlapping patients). We excluded articles
that reported on only a particular sample or selected patients
(e.g., studies using a selected group merely to assess the
reliability of measurements of tumor size). No articles were
excluded for any other reasons.
Our search strategies yielded 527 studies, which were
narrowed to 77 by reviewing the abstracts. These were then
reviewed in detail for eligibility for inclusion, and 22 studies
were chosen for analysis. In addition, manual search yielded
another 13 articles, for a total of 35 that contained data
relevant to this study. Primary outcome measures were death,
death from lung cancer, and tumor growth. The characteris-
tics of the patients included in the studies were recorded,
according to the specific questions to be addressed by our
review.
No formal analysis of study quality or publication bias
was possible among these retrospective studies. We included
data only on patients that met the definitions outlined in this
article for natural history, with a few exceptions when it was
evident that the outcomes would be similar to those meeting
the strict criteria. We included data from studies in which
most of patients (90%) were untreated. In some instances
data was not included in the calculations because the end
point or patient cohort was thought to be too dissimilar, but is
nevertheless depicted in the tables so the readers can judge
the appropriateness of the decision for themselves. In the
situations where deviations from the defined end points oc-
curred details of the particular circumstance are provided in
the footnotes of the respective table. Quantitative synthesis of
the results was limited to simple calculation of averages
among the relevant studies. So many factors were poorly
TABLE 1. Natural History of Untreated Advanced Stage NSCLC
Study N
How
Found
Clinical
Stage Environment Comments
Overall Survival
Death Due
to CaMST (mo) % 1-yr % 2-yr % 5-yr
aHyde et al.62 58–62 138 Routine I–IIIb VA All men (4)b (13)b (2)b (0)b,c —
aRoswit et al.63 58–66 246 Routine I–III VA All men 5 14 0 0 —
aHyde et al.64 58–72 293 Routine I–IIIb VA All men — — (4)b — —
Zelen et al.65 57–73 193 Routine III VA All men 4d 14d — — —
Paul et al.66 60–82 50 Routine III Canada — 5 12 0 0 —
Reinfuss et al.67 83–90 162 Routine III Poland — 4 9 0 0 100
Vrdoljak et al.68 80–87 17 Routine IIIa Croatia — 9 19 0 0 —
Leung et al.69 84–88 57 Routine III China — 9 30 5 0 —
eRaz et al.36 89–03 1,306 Routine IIIa Calif Registry 4 23 9 2 —
eRaz et al.36 89–03 7,248 Routine IIIb Calif Registry 2 12 5 0 —
fAverage 5 17 3 0
aHyde et al.62 58–62 328 Routine IV VA All men (2)b (6)b (1)b (0)b,c —
aHyde et al.64 58–72 775 Routine IV VA All men — — (1)b — —
Zelen et al.65 57–73 522 Routine IV VA All men 2d 6a,d 1 — —
Vrdoljak et al.68 80–87 65 Routine IV Croatia — 5 13 0 0 —
eRaz et al.36 89–03 12,840 Routine IV Calif Registry 2 8 4 0 —
fAverage 3 9 2 0
Inclusion criteria: studies of 20 patients reporting the natural history of untreated non-small cell lung cancer.
a Estimated from indirect data provided.
b Crude survival.
c 4-year survival.
d Average of squamous carcinoma, adenocarcinoma, and large cell.
e Untreated during the 1st 6 mo after diagnosis.
f Excluding values in parentheses.
Ca, cancer; Calif, California; mo, months; MST, median survival time (in months); VA, veterans administration hospitals (USA).
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described in these retrospective reports that a more sophisti-
cated quantitative analysis appeared inappropriate. Whenever
possible we tried to include details of the patient’s character-
istics and all of the results for the individual studies so that
the reader could assess the consistency of the results and the
appropriateness of combining the results for themselves.
DIRECT MEASUREMENT
Data on the survival of patients with untreated lung
cancer is summarized in Tables 1 and 2. These studies have
primarily involved lung cancers detected as part of the routine
practice of medicine. Many of these patients presented be-
cause of symptoms, although some lung cancers were likely
found incidentally on a chest radiograph taken for unrelated
reasons (especially among patients with stage I tumors). The
data demonstrates that survival of untreated patients is dis-
tinctively poor. For clinical stages I/II, III, and IV, respec-
tively, the median survival time (MST) is 10, 5, and 3
months; the 1-year survival 39, 17, and 9%; and the 5-year
survival only 2%, 0, and 0. Although there is a slight trend to
better long-term survival of patients with earlier stages of
disease, the effect is not pronounced, is related to lead time
(at least in part) and long-term survivors are rare. A small
trend can perhaps be perceived towards slightly better sur-
vival in more recent series among stage I/II and III patients
compared with older patient cohorts, but the effect is mar-
ginal. The survival is shown graphically in Figure 1 from one
of the largest series, involving almost 23,000 patients from
the California cancer registry.
In older series, dating back 40 and 50 years, it seems to
have been more acceptable to observe patients with lung
cancer without administering any active treatment. Therefore,
it may be that the patients in older series are more represen-
tative of patients in general. On the other hand, the relevance
of such old data to the current situation is questionable.
Besides the studies cited in Table 1 that reported specifically
on untreated patients, a comparison group is available from
studies of patients with advanced NSCLC who were random-
ized to either chemotherapy or basic supportive care during
the last 20 years. Two systematic reviews of such studies
TABLE 2. Natural History of Untreated Early Stage NSCLC
Study
Accrual
Years N How Found
Clinical
Stage Environment Comments
Overall Survival
Death Due
to CaMST (mo) % 1-yr % 2-yr % 5-yr
Vrdoljak et al.68 80–87 50 Routine cI, II Croatia — 13 56 13 0 —
Chadha et al.70 90–01 39 Routine cI, II USA Registry 12 26 0 0 49
Kyasa et al.71 91–98 70 Routine cI, II VA — 11 44 17 0 86
aWisnivesky et al.20 91–99 1,052 Routine cI, II SEER M  65 yr 6 30 14 3 90b
aWisnivesky et al.20 91–99 1,292 Routine cI, II SEER F  65 yr 9 40 19 5 90b
Average Routine cI, II 10 39 13 2 80
aHenschke et al.72 88–94 131 Routine cIa SEER 6–15 mm diam (24)c (81)c (48)c (39)c —
aRaz et al.36 89–03 571 Routine cIa USA Registry 13 53 33 9 —
Sobue et al.13 82–84 27 Routine cI Japan Matchedd 13 50 30 4 81
aRaz et al.36 89–03 1,432 Routine cI USA Registry 9 42 24 7 84
aWisnivesky et al.73 88–04 1,468 Routine cI SEER — (14)c (57)c (32)c (14)c 73
Chadha et al.70 90–01 26 Routine cI USA Registry 10 39 0 0 50b
McGarry et al.35 94–99 49 Routine cIe VA All M 14 62 38 — 53
fMotohiro et al.14 82–91 584 Routine cI Japan — (17)b,f (69)b,f (36)b,f (14)b,f —
Vrdoljak et al.68 80–87 19 Routine cIb Croatia — 17 80 20 0 —
aRaz et al.36 89–03 861 Routine cIb USA Registry 8 46 18 5 —
aRaz et al.36 89–03 128 Routine cII USA Registry 5 33 13 3 —
aWisnivesky et al.73 88–04 140 Routine cII SEER — (14)c (37)c (20)c (10)c 78
Vrdoljak et al.68 80–87 31 Routine cIIb Croatia — 11 40 8 0 —
gAverage Routine cI, cII 11 49 22 4 70
hFlehinger et al.15 73–78 29 CXR screen cI USA — (25)c,h (88)c,h (57)c,h (9)c,h —
Sobue et al.13 82–84 42 CXR screen cI Japan — 25 76 48 14 80
fMotohiro et al.14 82–91 215 CXR screen cI Japan — (27)f (80)f (56)f (24)f —
gAverage CXR screen cI 25 76 48 14 80
Inclusion criteria: studies of 20 patients reporting the natural history of untreated non-small cell lung cancer.
a Classified as untreated if no treatment for 6 mo, does not account for later treatment.
b Estimated from indirect data provided.
c Disease free survival.
d Matched by gender and age with CXR screen detected cases.
e Included 9% stage II tumors.
f Various non-surgical treatments used, none of which demonstrated a significant effect on survival.
g Excluding values in parentheses.
h 24% of patients received RT (either palliative or curative intent).
Ca, cancer; CXR, chest radiograph; Diam, diameter; F, women; M, men; mo, months; MST, median survival time (in months); RT, radiotherapy; SEER, surveillance,
epidemiology, and end results registry (USA); VA, veterans administration hospitals (USA); yr, years old (patient age).
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revealed little difference in MST (3.7 and 4.1 months) com-
pared with the data in Table 1.8,9 Taken together, the data
among predominantly stage IV patients suggests a slight
trend to better survival in more recent times (a gain of
approximately 2 weeks for each decade since the 1960s).
Series of patients with early stage NSCLC who are not
treated, suffer from the criticism that these patients are highly
selected by negative factors and should therefore be expected
to exhibit poor survival. Countering this is the observation
that the majority of patients, in fact, died of lung cancer in
those series in which this data was recorded. Although the
suspicion has been raised that there is an inherent bias to
attribute any death in a cancer patient to the cancer (sticky
diagnosis or attribution bias), formal analysis has demon-
strated that this is relatively infrequent.10–12 Furthermore, this
is probably even less prevalent in patients with severe co-
morbidities, in whom the comorbidities seemed to over-
shadow the importance of treating a lung cancer (particularly
for stage I).
A trend to better survival is suggested among pa-
tients with lung cancer that participated in mass screening
programs using chest radiographs (Table 2). This is based
primarily on one study from Japan, which found a MST of
25 months and a 5-year overall survival of 14%.13 This is
corroborated by another study from Japan, which, how-
ever, included patients who received a variety of nonsur-
gical treatments (none of which significantly affected sur-
vival).14 A third study from the Memorial Sloan Kettering
chest radiograph (CXR) and sputum screening project
conducted a decade earlier reported only disease free
survival.15 Although it is more difficult to compare, it
seems that short- and intermediate-term survival was sim-
ilar, whereas 5-year survival was worse than in the Japa-
nese series. Furthermore, the patient cohort is not “clean”
in that 24% received radiotherapy, although it is not clear
at what dose and whether this was intended as curative or
palliative treatment. Nevertheless, when all of the data is
viewed as a whole, there is at least a suggestion that the
natural history of lung cancer detected as part of a CXR
screening program may be better than for patients present-
ing in a more routine fashion). Of course, this apparently
longer natural history in screen detected cases includes the
effects of lead time bias, and does not necessarily imply a
difference in tumor biology. No data is available on the
natural history of patients with lung cancer detected as a
result of mass screening using CT.
ESTIMATION FROM TUMOR GROWTH
Mean Tumor Doubling Time
Several studies have retrospectively analyzed previous
imaging studies to measure tumor volume doubling time
(VDT). These are summarized in Table 3. The mean VDT is
approximately 135 days for patients diagnosed during routine
medical care, 150 days in screening studies involving chest
radiographs, and 480 days in screening studies involving CT
(Figure 2). This data is fairly consistent among studies in-
volving a particular method of detection (routine care, CXR
or CT screening), and thus is quite convincing that CT screen-
ing in particular identifies a different patient group. No real trend
is apparent in more recent studies compared with older series.
The VDT does not seem to be influenced by the reason for the
interval between imaging studies, the length of the interval, the
years involved or the geographic location of the study.
A more detailed analysis reveals that women consis-
tently have longer mean doubling times than men by a factor
of approximately 2 (range 1.4–2.9).16–19 This gender differ-
ence seems to hold true within each method of detection
(VDT of approximately 250 versus 125 days in women
versus men with detection by CXR screening and 600 versus
350 days in CT screen detected, respectively). A survival
advantage for women over men was seen for each cell type
except squamous carcinoma in a large SEER database study
of treated and untreated patients more than 65-year-old with
cI, II NSCLC.20 This suggests that the better survival in
women is not merely because of a greater proportion of
adenocarcinoma or bronchoalveolar carcinoma (BAC), but
reflects a gender-specific difference in biological behavior.
Two studies reported progressively longer VDT for
solid, semisolid, and ground glass opacity (GGO) lesions
detected by means of CT screening (approximately 150, 475,
and 850 days respectively).16,18 However, another study found
little difference among these radiographic categories (approxi-
mately 500, 570, and 470 days, respectively, p  NS).17
Several studies (Table 4) have consistently documented
progressively longer mean VDT by histologic types: squa-
mous carcinoma  adenocarcinoma  BAC  atypical
alveolar hyperplasia. This progressive trend seems to be
consistent within several methods of detection. The trend to a
longer mean VDT is not limited only to BAC, but is seen with
adenocarcinoma as well. However, this data is of limited use
to the clinician because the histologic type is generally not
known until after resection has been accomplished. It is
noteworthy that CT screen detected cases as compared with
routinely detected cases have a markedly longer VDT for
FIGURE 1. Survival of 23,954 patients with NSCLC
who did not receive surgical resection, chemotherapy or
radiotherapy.36
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BAC and adenocarcinoma, but there is little difference in
patients with squamous carcinoma. It is possible that CT
screening has little impact on tumors arising in the airways,
(i.e., squamous carcinoma) because of poor visualization of
these areas on CT.
Distribution of Tumor Doubling Times
The data on mean tumor doubling times suggests that
the growth rate varies according to the method of detection,
and other factors such as gender, histologic type, and possibly
the radiographic appearance. These mean values, however,
obscure the broad spectrum of doubling times, which are
summarized in Table 5. This data clearly demonstrates that
there is a broad distribution of tumor doubling times. Fur-
thermore, a marked trend in the distribution of VDT is seen
according to the method of detection. In patients undergoing
routine care and in CXR screening studies most of tumors
have a relatively short VDT (250 days), whereas in CT
screening studies a much broader distribution is seen extend-
ing to a very long (400 days) VDT (Figure 3). The study by
Winer-Muram et al., is somewhat of an outlier, with a
substantial portion (26%) of routine care detected patients
having a VDT of more than 400 days.21 A closer look,
however, discloses that the patients in this study were limited
to stage I lung cancers seen on a CT scan (although not part
of a CT screening program). The decision to exclude this
study can be challenged; if it is included the percentages
become 41, 42, 11, and 7% for VDT categories of less than
100, 100 to 249, 250 to 399 and 400 days, respectively.
Factors other than the method of detection do not seem
to influence the VDT distribution. The time period over
which patients were enrolled in the studies does not seem to
influence the VDT distribution. Differences exist between
lung cancers seen in different parts of the world (e.g., a high
proportion of squamous cell cancer in Europe, adenocar-
TABLE 3. Mean Doubling Time
Study N
Years of
Accrual
How
Detected
Reason for
Interval
Interval
(mo) Environment
Other
Comments
Mean
VDT (d)
Spratt et al.25 34 40–61 Routine — — USA 88
Garland et al.74 41 55–61 Routine — — USA 162
Geddes et al.34 228 60–75 Routine — — Eu/USA 102
Mizuno et al.33 50 75–80 Routine — — Japan 136
Usuda et al.19 45 85–86 Routine Misseda 3–12 Japan 167
Arai et al.75 96 89 Routineb Missed/Dx obs 6a Japan 139c
dJennings et al.59 149 96–04 Routine Various 4e USA (161)d
gAverage Routine 136
Yankelowitz et al.76 44 71–76 CXR screen Missed 12 USA MLP, all M 101
Yankelowitz et al.76 43 74–78 CXR screen Missed 12 USA MSK, all M 144
Usuda et al.19 129 85–86 CXR screen Missed 3–12 Japan 163
Arai75 138 89 CXR screen Missed/Dx obs 6a Japan 190
Average CXR screen 150
Hasegawa et al.16 61 96–98 CT screen Misseda 5–15 Japan 452
Sone18 45 96–98 CT screen Missed, w/u — Japan 470
gTakashima et al.57 20 96–98 CT screen w/u 3 Japan 1–2 cm diam (508)h
Lindell et al.17 48 99–03 CT screen Dx obs — USA 518
gAverage CT screen 480
Inclusion criteria: studies of 20 patients reporting tumor doubling times among patients with non-small cell lung cancer.
a In most patients.
b Patients detected as part of unrelated medical care or because of symptoms of lung cancer.
c Estimated by combining patients detected incidentally and because of symptoms.
d Pathologic stage I patients, seen on a CT scan (but not through a CT screening program).
e Median.
f Excluding values in parentheses.
g Included patients with atypical alveolar hyperplasia (15%).
h Data only for the 56% that increased in size over a mean of 93 d between scans (42–120 d); rest were stable.
CT, computed tomography scan; CXR, chest radiograph; Diam, diameter; Dx obs, diagnostic period of observation; Eu, europe; M, men; MLP, Mayo lung project; mo, months;
MSK, memorial Sloan Kettering study; VDT, volume doubling time; w/u, delay due to work up.
FIGURE 2. Mean doubling times observed among human
non-small cell lung cancers, by the method of detection.
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cinoma in North America, a higher proportion of BAC and
epidermal growth factor receptor (EGFR) mutations in
Japan). However, there does not seem to be a correlation of
VDT distribution with geographic location.
The proportion of patients with a long VDT (400
days) seems to be particularly large in women (59 and 37%
in two studies) in CT screening studies (versus 36 and 11% in
men).17,18 The proportion with long VDT is dramatically
TABLE 4. Mean Doubling Time by Histologic Type
Study
n AAH/
BAC/Ad/Sq
Years of
Accrual
How
Detected Location
Volume Doubling Time (d)
AAH BAC Ad Sq
Spratt et al.25 –/–/8/13 40–61 USA — — 118 70
Garland et al.74 –/–/7/22 55–61 Routine USA — — 222 128
Geddes et al.34 –/–/60/111 60–75 Routine Eu/USA — — 161 88
Mizuno et al.33 –/–/23/22 75–80 Routine Japan — — 178 103
aJennings et al.59 –/19/51/48 96–04 Routine USA — 250 166 132
Average Routine 250 169 104
Usuda et al.19 –/–/86/67 85–86 CXR screenb Japan — — 223 105
Average CXR screen 223 105
Hasegawa et al.16 –/–/49/8 96–98 CT screen Japan — — 533 129
Sone et al.18 –/13/23/4 96–98 CT screen Japan — 747 448 (134)c
Lindell et al.17 –/9/22/8 99–03 CT screen USA — 780 746 103
dTakashima et al.57 3/8/6/3 96–98 CT screen Japan (988)c,d (567)d (384)d (122)d
eAverage CT screen 764 576 122
Inclusion criteria: studies of 20 patients reporting tumor doubling times and histologic types of non-small cell lung cancer.
a Clinical stage I patients, found by CT scan (but not in a CT screening program).
b 75% of patients were enrolled in a screening study.
c Less than 5 patients in this category.
d Data only for the 56% that increased in size over a mean of 93 d between scans (42–120 d); rest were stable.
e Excluding values in parentheses.
AAH, atypical alveolar hyperplasia; Ad, adenocarcinoma; BAC, bronchioloalveolar carcinoma; CT, computed tomography scan; CXR, chest radiograph; Eu, europe; Sq,
squamous cell carcinoma.
TABLE 5. Tumor Doubling Time Distribution
Study N
How
Detected
Years
Studied
Other
Charac. Location
% with Volume Doubling Time of (in d)
<100 100–249 250–399 400–799 >800
Garland et al.74 40 Routine 55–61 — USA 48 38 8 4 2
Weiss et al.77 91 Routine 59–62 — USA 48 40 7 3 1
Steele et al.24 67 Routine 59–62 VA USA 33 52 10 5 0
Weiss et al.26 47 Routine 59–65 — USA 30 55 13 2 0
Kerr et al.78 23 Routine 77–83 — England 61 26 13 0 0
aWiner–Muram et al.21 50 Routine 96–01 VA USA (26)a (36)a (12)a (8)a (18)a
Average Routine 44 42 10 3 — 3 — 1
Arai et al.75 237 CXR screenb 89 — Japan 37c 29c 22d 10d,e 4e
Usuda et al.19 159 CXR screenb 85–86 — Japan 47 37 6 7 3
Yankelowitz et al.76 44 CXR screen 71–76 MLP, all M USA 48 45f 5f –– 2 —
Yankelowitz et al.76 43 CXR screen 74–78 MSK, all M USA 23 56f 14f –– 7 —
Average CXR screen 39 12 195 8 195
Hasegawa et al.16 61 CT screen 96–98 — Japan 24 31 19 21 5
Sone et al.18 45 CT screen 96–98 — Japan 18 20 18 27 18
Lindell et al.17 48 CT screen 99–03 — USA 33 40 — — 27 —
Average CT screen 29 31 19 — — 27 — —
Inclusion criteria: studies of 20 patients reporting a distribution of doubling times among patients with non-small cell lung cancer.
a Pathologic stage I patients, seen on a CT scan (but not through a CT screening program).
b 60–75% of patients were enrolled in a screening study.
c Threshold of 120 d.
d Threshold of 480 d.
e Threshold of 960 d.
f Estimated from indirect data reported.
CT, computed tomography scan; CXR, chest radiograph; M, men; MLP, Mayo lung project; MSK, memorial Sloan Kettering study; VA, veterans administration hospital system.
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increased for GGO lesions with a corresponding decrease in
the percent with a short (100 days) VDT (Figure 4).16–18 In
fact approximately 50% of lung cancers that had a GGO
appearance had a VDT of more than 800 days (2.2 years) in
two CT screening studies.16,18 Semisolid lesions also have a
substantial portion (approximately 45%) with long VDT
(400 days), but include some rapidly growing tumors (ap-
proximately 10%). In contrast, solid lesions rarely grow
slowly (approximately 10%), and many have short VDT
(approximately 45%).16–18
There is no evidence that older patients have more
slowly growing tumors in the only study providing data
regarding this (involving CT screening).18 In fact, the oppo-
site seems to be true, with an increase in the proportion with
short (100 days) VDT in older patients (0, 18, and 36% of
patients aged 60, 60–69, and 70, respectively) and argu-
ably a decreasing proportion with long (400 days) VDT
(42, 59, and 18% of patients aged 60, 60–69, and 70,
respectively).18 It is unknown how characteristics such as risk
factors (e.g., smoking) or willingness to participate in screen-
ing study may have influenced these results.
Models of Tumor Growth
To apply the data on observed doubling times to predict
the natural history of lung cancer, a review of some concepts
of tumor growth is necessary. The two main models of tumor
growth are reviewed, and some of the general implications
and pitfalls of estimating the natural history.
Exponential Growth
Early laboratory studies included a classic series of
elegant experiments involving a murine leukemia model
known as L1210.22 In this murine model essentially all of
these tumor cells were actively dividing at a constant rate,
and could be traced back to a single malignant cell of origin.
This led to the widespread adoption of the concept of expo-
nential growth, a model of tumor growth that is still often
used today.23 This model fit extremely well with the observed
proliferation of leukemia cells in the mouse L1210 model.
Early observations of primary lung cancers and metastatic
pulmonary nodules on serial CXR were consistent with ex-
ponential growth, although the period of observation was
limited.24–26
The exponential model postulates that all of the cells
are in a growth phase and dividing at a constant rate through-
out the life of the tumor. With each doubling time the volume
of the tumor doubles; simple mathematics correlates each
doubling of volume with an increase in the diameter of
approximately 1.26 (the cube root of 2). Assuming the initial
tumor cell has a diameter of 10 m, it would take 30
doublings to reach a diameter of 1 cm, 35 doublings to reach
3 cm, and 40 doublings to reach a diameter of 10 cm (and a
weight of 1 kg). A tumor of this size in the chest is likely
to cause significant life-threatening effects, and therefore the
usually accepted time of death is estimated to be at about 40
to 41 doubling times (Figure 5).
Gompertzian Growth Model
Another model, known as the Gompertzian model,
stems from an actuarial model that has been applied to tumor
FIGURE 3. Proportion of patients with very short (100
days) or very long (400 days) tumor doubling times
according to the method of lung cancer detection.
FIGURE 4. Proportion of tumor doubling time categories
by radiographic appearance among CT screen detected can-
cers. A, Hasegawa M, et al. Br J Radiol 2000;73:1252–59;16
B, Sone S, et al. Lung Cancer 2007;58:329–41;18 C, Lindell
RM, et al. Radiology 2007;242:555–62;17 VDT: volume dou-
bling time.
FIGURE 5. Schematic of exponential growth of a cancer,
with time expressed as number of volume doublings. (From
Geddes DM. Br J Dis Chest 1979;73:1–17.34)
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growth. This model also assumes that rate of tumor cells
division is constant, which has been demonstrated to be the
case.27 However, the fraction of tumor cells that is in a
growth phase decreases over time. This might be due to the
tumor outstripping its blood and nutrient supply, excess
excretory products, contact inhibition, or simple crowding.28
This model predicts a progressively longer VDT as the tumor
size increases. Mathematically the Gompertz equation states
that tumor growth at each instant is exponential, but with a
growth constant (growth fraction) that is simultaneously de-
creasing exponentially.28
Clinical observations over longer periods have shown
that most human tumors follow a Gompertzian growth curve,
in which growth slows as the tumor gets larger (with the
possible exception of Burkitt’s lymphoma which follows a
more exponential growth curve).27,29 In fact, Gompertzian
growth is also observed in most animal models (Figure
6).28,30,31 The maximum growth rate occurs when the tumor
is approximately one-third of its maximal size.27 The
Gompertzian model predicts a shorter period of preclinical
growth than the exponential model, and longer survival
after diagnosis.29
Phases in the Life of a Cancer
It is often assumed that a cancer starts with malignant
transformation of a single cell. This cell grows, but has a
prolonged period during which the developing tumor is so
small it is undetectable by all means. At some point, the
tumor is sufficiently large to be detectable if an imaging study
is done (i.e., CT or positron emission tomography), but it is
still too small to cause any clinical symptoms. Eventually a
change in the patient’s well-being prompts medical attention
and a diagnosis is made. The time from the initial malignant
transformation to clinical detection is the preclinical phase,
and generally is at least 3⁄4 of the entire life of the tumor. If
a diagnosis is made by an intercurrent imaging study before
the onset of symptoms, the time between this incidental
diagnosis and the usual diagnosis at clinical presentation
represents the lead time. The time between the diagnosis and
the patient’s death is the survival time. Obviously, if diagno-
sis is made earlier, the survival time will be longer (even
without any active treatment) because of the lead time.
On the other hand, malignant tumors lead to death not
only because of growth of the primary tumor mass, but
because of the capacity of tumors to metastasize to distant
sites. The historical concept has been abandoned that distant
metastases only occurs when the local lymphatics have be-
come overwhelmed and can no longer contain the tumor. The
question “When do tumor cells reach the bloodstream? ” has
given way to the question “What gives a circulating tumor
cell the ability to successfully implant and grow? ” Sensitive
analyses have shown that circulating tumor cells are com-
mon, even in early stage cancers. For example, circulating
tumor cells were detected by reverse transcription-polymer-
ase chain reaction in 40% of 71 patients with NSCLC and
30% of 15 patients with small cell lung cancer patients.32 The
presence of circulating tumor cells was unrelated to tumor
stage. An acquired genetic change in the tumor cells (i.e., an
angiogenesis factor) may be what determines how and when
circulating cells develop the ability to form actively growing
metastases. Alternatively, it may be changes in the host
immune system or microenvironment (i.e., chemokines) that
are the key. An understanding of these factors has implica-
tions on the ability to predict natural history from observation
of the tumor doubling time during a limited period.
Predictions on the Natural History from
Doubling Times
It is possible, using the tumor diameter and the ob-
served doubling time, to calculate for an individual patient
what the natural history would be if the tumor followed an
exponential growth pattern. One study has directly compared
actual survival in individual patients with that predicted from
the observed doubling time, and found remarkable correlation
among nonresected patients with survival time as predicted
by the exponential model (r  0.88, p  0.01).33 These were
patients diagnosed with lung cancer during routine medical
care (no screening involved) in whom prior chest radiographs
were available. It is not clear why there was a delay in
diagnosis (or treatment). Surgical resection resulted in mark-
edly better survival than predicted by the model, but other
treatments (given to 24 of 26 nonresected patients) seemed to
have little benefit, which is perhaps not surprising given the
state of affairs around 1980. Thus this study provides fairly
direct data in support of the exponential growth model,
although the data is not “clean” (i.e., involving truly untreated
patients).
One can attempt to validate growth models in general
terms by comparing predictions based on average tumor
sizes, average doubling times with average observed survival.
Studies have reported an average tumor diameter of 33 mm
among cancers detected during routine care,33–37 30 mm in
patients undergoing CXR screening,38–40 and 16 mm in
patients undergoing CT screening (all scans).1,16,17,37,38,41–45
For patients detected purely by an incidence scan during the
course of CT screening the average size is approximately
13 mm.1,42,44
FIGURE 6. Gomperztian growth curve demonstrated by
observed average growth rates in 100 mice after implanta-
tion of adenocarcinoma. The solid and dotted line represents
a best-fit Gompertz function. (From Schabel FM. Cancer
1975;35:15–24.28)
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Table 6 tabulates results of calculations based on re-
ported average tumor sizes and doubling times according to
the method of detection using the exponential growth model.
The calculated survival time based on mean size and mean
doubling time is approximately 2.2, 2.7, and 12 years for
routine, CXR-screen and CT-screen detected NSCLC, re-
spectively. This is markedly longer than what has been
reported in Tables 1 and 2 for routine detection cases,
although it is similar for stage I CXR screen detected cases.
Furthermore, the estimate of the entire life of the tumor is 15,
17, and 54 years. Even 15 years is difficult to believe, and 54
years seems practically impossible. Thus these estimates call
into question the validity of predictions about the survival
time based on observed doubling times and the exponential
model (including the assumption that death occurs on average
after 40–41 doublings).
Predicting growth over the entire life of a tumor using
the Gompertzian model is more complex. This is in part
because the doubling time varies depending upon the size of
the tumor. Thus the applicability of the observed doubling
time must be estimated by taking into account the tumor size
during the period of observation. In general terms, however,
the Gompertzian model would predict that the growth rate
before clinical detection would be more rapid than the expo-
nential model, and slower afterward. Thus the survival times
after clinical detection would likely be two to three times
longer than predicted by the exponential model. These pre-
dictions do not fit the observed survival times for lung
cancers detected by routine care or by CXR screening (no
observations exist with which to correlate survival of CT
detected lung cancers).
IMPLICATIONS OF NATURAL HISTORY ON
PATIENT MANAGEMENT
The observed survival of untreated patients in whom
lung cancer is detected as part of routine care is uniformly
poor, suggesting that these patients should be managed ag-
gressively and expeditiously. The median survival of patients
with routinely detected clinical stage I, II tumors is only
about 10 months if untreated. A brief trial of antibiotics to
differentiate between infection and malignancy may some-
times be justified. However, in many instances such a “diag-
nostic delay” is not justified because the radiographic appear-
ance so clearly suggests lung cancer and not infection
(discrete, solid, spiculated mass). Unless the radiographic
appearance is strongly suggestive of scar, a period of delay to
observe growth does not seem to be warranted. Furthermore,
a prolonged sequential work-up involving a battery of imag-
ing tests and biopsy procedures often takes many weeks to
complete. Prompt referral to a specialist appears to result in a
more rapid and streamlined evaluation and initiation of treat-
ment. This has led the relevant medical organizations in
several countries (Great Britain, Canada, France, Sweden) to
either mandate or strongly recommend through guidelines
that patients with a suspicion of lung cancer be referred and
seen promptly (within 1–2 weeks) by a thoracic specialist, in
general in conjunction with a multidisciplinary team. How-
ever, the amount of benefit that is realized from rapid
evaluation and initiation of treatment is unclear.46 It is
suggested that the patient be seen in an organized multi-
disciplinary program,47,48 because of data suggesting that
this promotes the delivery of evidence-based care and
improves outcomes.49 –53
The data regarding the distribution of tumor doubling
times shows that lung cancers involve a wide spectrum of
growth rates. A broader appreciation of this fact is warranted,
because CT imaging in particular appears to affect the spec-
trum of disease that is encountered. The presence of CT
screening programs and the increased prevalence of CT
imaging (outside of a CT screening program) makes this
observation particularly important at this time. Direct natural
history data to corroborate this observation, however, is not
available. Nevertheless, the increasingly broad spectrum of
disease leads to speculation that with a better understanding
it may be possible to match the aggressiveness of the treat-
ment to the aggressiveness of the particular tumor. Obvi-
ously, this will require not only methods to define average
characteristics of types of tumors, but confidence that one can
define the aggressiveness of the tumor of an individual
patient.
The spectrum of lung cancer detected as a result of CT
screening is markedly different than that of patient diagnosed
during routine medical care. Tumors found in CT screening
programs have markedly longer doubling times, and a sub-
stantially greater proportion with very long (400 days)
doubling times. There is little difference between routine care
detected tumors and CXR screen detected tumors, although a
slight trend is apparent. Surprisingly, there is little difference
TABLE 6. Estimated Relevant Clinical Intervals Based on Tumor Doubling Timea
How Detected
Mean
VDT (d)
Mean
Diam (mm)
# DT
Elapsed
# DT
Left
Mean Survival Time (in Years, Untreated)
1st Cell to
Detection
Detection to
Death
1st Cell
to Death
Routine 136 33 35 6 13 2.2 15
CXR screen 150 30 34.5 6.5 14 2.7 17
CT screen 480 16 32 9 42 12 54
a Survival times over 3 yr rounded to nearest integer. Calculations made based on the classic assumptions of the exponential growth model: a cell diameter of 10 m, spherical
cells, a constant growth rate and death at a diameter of 13 cm (41 doublings).
CT, computed tomography scan; CXR, chest radiograph; Diam, diameter; # DT elapsed, number of doubling times elapsed between development of the 1st malignant cell and
clinical detection (calculated by average size at detection); # DT left, number of doubling times left from detection to death (assuming death at 41 total doublings); VDT, volume
doubling time.
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in routine care detected cancers currently compared with
those detected decades ago. A minor trend towards less
rapidly growing tumors in more recent times is suggested,
perhaps related to a greater prevalence of imaging for indi-
viduals in general.
Several important implications follow from the obser-
vations that a spectrum of aggressiveness exists among lung
cancers and that the proportion of patients along the spectrum
is affected by the method of detection, and other character-
istics such as the radiographic appearance (GGO versus
semisolid versus solid). First, it is probably inappropriate to
use data generated from routinely detected patients to make
estimates about the outcomes of CT screen detected patients.
This applies to an estimate of a potential mortality benefit as
well as an assessment of cost-effectiveness. Similarly, we
must be careful in the interpretation of phase II studies of
novel treatment approaches such as Radiofrequency Ablation
and Stereotactic radiosurgery. Second, evaluation of treat-
ments for less aggressive tumors may require a prolonged
period of follow-up before the true impact of the treatment
can be assessed. Finally, the greater prevalence of indolent
tumors raises the question that over-treatment and over-
diagnosis may be a substantial risk in some settings.
Unfortunately, models of tumor growth do not seem to
correlate well with estimations derived from observed dou-
bling times. Thus predictions about the natural history made
from doubling times are not currently accurate enough to
justify not treating a diagnosed lung cancer in most clinical
situations. Although observation alone may well turn out to
be appropriate for some patients, this must be studied further.
This conclusion is further strengthened by the lack of under-
standing of the relationship between (indolent) tumor growth
and the development of distant metastases.
A particularly poignant issue is the management of
patients with a GGO. The data regarding VDT suggests that
this group has a high proportion of slow growing tumors
(40–90% with VDT of400 days among CT screen detected
tumors). Several factors contribute to the difficulty in defin-
ing the appropriate management of a GGO. The correlation
between radiographic characteristics and histologic diagnosis
(atypical alveolar hyperplasia, BAC, or well differentiated
adenocarcinoma) is unclear.54–56 Furthermore, in a substan-
tial portion of patients with a GGO the presence of a malig-
nancy is associated with an increase in the density of the
lesion without growth, or even with shrinkage of the le-
sion.17,57–59 Thus a GGO may represent a benign lesion or a
cancer, and growth alone does not always differentiate these.
The data cited in this review stems largely from formal
screening studies, and an important question is how well this
applies to patients who are not participating in a screening
program, given the rapidly increasing number of CT scans
that are done for unrelated reasons.60 Recent studies among
treated patients have suggested the same good prognosis
among patients with a CXR screen detected lung cancer and
one detected incidentally by a CXR done for other reasons
during work-up of an unrelated medical condition—in con-
trast to a lung cancer detected by routine clinical presenta-
tion.61 This observation held up even among stage pI tumors,
suggesting that the method of detection, whether part of a
formal screening program or not, selected patients with a
different biological behavior.61 No comparison is available
between lung cancers detected incidentally by a CT scan and
one detected in a CT screening program.
Many questions remain about the natural history of
lung cancer, and insufficient and conflicting data exists in
many areas. Nevertheless, two main concepts clearly emerge.
First, untreated lung cancer as detected during routine clinical
care is rapidly fatal, even among patients with stage I
NSCLC. However, a second central concept is that the
spectrum of growth rates of lung cancer seems to be changing
significantly. The evidence is strong and consistent that CT
screening identifies a somewhat different cohort of patients
with lung cancer that includes many more patients with slow
growing tumors. This phenomenon may also extend to GGOs
that are discovered incidentally because of an increasing
frequency of imaging in general. Thus our changing health
care environment demands that we view lung cancer as a
spectrum of shades of gray. It is important that we develop a
thorough appreciation of the range of disease behavior, be-
cause it is crucial to appropriately evaluate data regarding
practically every aspect of lung cancer—including screening,
diagnosis, staging, and treatment.
CONCLUSIONS
Review of the data on the natural history of lung cancer
leads to the following conclusions:
1. Lung cancer as diagnosed during routine medical care is
rapidly fatal, even among clinical stage I tumors. Pa-
tients who are found to have a lesion suspicious for lung
cancer should be referred promptly to a specialist for
evaluation. A period of observation by the internist or
family practitioner is not justified other than possibly
for a brief period to exclude pneumonia. There is only
a minimal trend to better survival in more recent years.
2. There is a wide variation in tumor growth rates. Lung
cancer is a heterogeneous disease with a spectrum of
growth characteristics.
3. The proportion of slowly growing tumors VDT (400
days) is substantially increased in patients diagnosed as
part of screening program (especially CT screening). It
is inappropriate to apply data regarding the natural
history of lung cancer from populations of patients
detected during routine care to patients detected as part
of a CT screening program.
4. The larger proportion of slowly growing tumors in CT
screening programs suggests that over-treatment and
over-diagnosis may exist.
5. Limited data suggests that the increase in indolent
tumors seen in CT screening programs may also be
present among tumors found by incidental (nonscreen-
ing) CT imaging.
6. Models of tumor growth are not sufficiently clear to
allow accurate prediction of the natural course from
knowledge of the VDT of the tumor.
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7. Awareness of the changing spectrum of aggressiveness
among lung cancers is needed to correctly interpret the
results of non-randomized studies.
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